Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors

Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors

Daratumumab is an anti-CD38 directed monoclonal antibody approved for the treatment of multiple myeloma (MM) and functions primarily via Fc-mediated effector mechanisms such as complement-dependent cytotoxicity (CDC), antibody-dependent cell cytotoxicity (ADCC), antibody-dependent cellular phagocyto...

Full description

Bibliographic Details
Main Authors: Wojciech Dawicki, Kevin J.H. Allen, Rubin Jiao, Mackenzie E. Malo, Muath Helal, Mark S. Berger, Dale L. Ludwig, Ekaterina Dadachova
Format: Article
Language:English
Published: Taylor & Francis Group 2019-08-01
Series:OncoImmunology
Subjects:
multiple myeloma
daratumumab
225actinium
microspect/ct
radioimmunotherapy
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1607673

Internet

http://dx.doi.org/10.1080/2162402X.2019.1607673

Similar Items